Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Lopes Alves, Isadora
  • dc.contributor.author Gispert López, Juan Domingo
  • dc.contributor.author Molinuevo, José Luis
  • dc.contributor.author AMYPAD Consortium
  • dc.date.accessioned 2021-03-12T06:48:10Z
  • dc.date.available 2021-03-12T06:48:10Z
  • dc.date.issued 2020
  • dc.description.abstract Introduction: The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Prognostic and Natural History Study (PNHS) aims at understanding the role of amyloid imaging in the earliest stages of Alzheimer's disease (AD). AMYPAD PNHS adds (semi-)quantitative amyloid PET imaging to several European parent cohorts (PCs) to predict AD-related progression as well as address methodological challenges in amyloid PET. Methods: AMYPAD PNHS is an open-label, prospective, multi-center, cohort study recruiting from multiple PCs. Around 2000 participants will undergo baseline amyloid positron emission tomography (PET), half of whom will be invited for a follow-up PET 12 at least 12 months later. Results: Primary include several amyloid PET measurements (Centiloid, SUVr, BPND , R1 ), and secondary are their changes from baseline, relationship to other amyloid markers (cerebrospinal fluid and visual assessment), and predictive value of AD-related decline. Expected impact: Determining the role of amyloid PET for the understanding of this complex disease and potentially improving secondary prevention trials.
  • dc.description.sponsorship The project leading to this paper has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115952. This Joint Undertaking receives the support from the European Union's Horizon 2020 research and innovation programme and EFPIA. FB is supported by the NIHR UCLH biomedical research center.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Lopes Alves I, Collij LE, Altomare D, Frisoni GB, Saint-Aubert L, Payoux P, et al. Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimers Dement. 2020; 16(5):750-8. DOI: 10.1002/alz.12069
  • dc.identifier.doi http://dx.doi.org/10.1002/alz.12069
  • dc.identifier.issn 1552-5260
  • dc.identifier.uri http://hdl.handle.net/10230/46736
  • dc.language.iso eng
  • dc.publisher Wiley
  • dc.relation.ispartof Alzheimers Dement. 2020; 16(5):750-8
  • dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/115952
  • dc.rights © 2020 The Authors. Alzheimer’s & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer’s Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in anymedium, provided the original work is properly cited and is not used for commercial purposes.
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri https://creativecommons.org/licenses/by-nc/4.0/
  • dc.subject.keyword Amyloid
  • dc.subject.keyword Positron emission tomography imaging
  • dc.subject.keyword Preclinical and prodromal Alzheimer's disease
  • dc.subject.keyword Secondary prevention
  • dc.title Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Departament de Medicina i Ciències de la Vida)
Documents OpenAIRE (Open Access Infrastructure for Research in Europe)